2-(N-benzyl-α-iminoethyl)-phenol | 365276-81-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 2-(N-benzyl-α-iminoethyl)-phenol
• CAS: 365276-81-9
• 化学式: C₁₅H₁₅NO
• 分子量: 225.29
• InChiKey: DNSDMSAATMZYNW-FOWTUZBSSA-N

物化性质

• 沸点：
  343.2±42.0 °C(Predicted)
• 密度：
  1.03±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  17.0
• 可旋转键数：
  3.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  32.59
• 氢给体数：
  1.0
• 氢受体数：
  2.0

反应信息

• 作为反应物：
  描述：

  2-(N-benzyl-α-iminoethyl)-phenol 在 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 水 、 溶剂黄146 为溶剂， 反应 3.5h， 生成 N-benzyl-N-(2-phenyl-4H-chromen-4-ylidene)amine
  参考文献：
  名称：

  Acylation of o-Imidoylphenol Lithium Dianions: Synthesis of 4H-Chromen-4-ylidenamines

  摘要：

  A method is described to obtain 4H-chromen-4-ylidenamines 4, through the reaction of o-imidoyl phenol dianions 2' with aromatic esters and subsequent acid cyclisation of the 3-(2-hydroxyphenyl)-3-(amino)-1-phenylprop-2-en-1-ones 3 obtained. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4020(99)01029-7
• 作为产物：
  描述：

  2'-羟基苯乙酮 、 苄胺 在 magnesium sulfate 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 以89 %的产率得到2-(N-benzyl-α-iminoethyl)-phenol
  参考文献：
  名称：

  合理设计的新型苯恶唑啉合酶抑制剂：化学合成和生物学评价，加速新型抗分枝杆菌抗生素的发现

  摘要：

  耐药结核病（DR-TB）临床病例的不受控制的传播需要迫切发现具有新作用机制的新化学型。在这里，我们报告了通过靶向苯基恶唑啉合酶（MbtB）的环化（Cy）结构域，合理设计的新型过渡态类似物（TSA）的化学合成，苯基恶唑啉合酶（MbtB）是条件必需的铁载体生物合成途径的关键酶。在生物测定指导下优先在缺铁和富铁培养基中对 TSA 类似物进行评估，以了解针对一组致病性和非致病性分枝杆菌菌株的靶标优先性，我们发现了一个热门产品，即 TSA-5。分子对接、动力学和 MMPBSA 计算使我们能够理解 TSA-5 在 MbtB_Cy 活性位点袋上的稳定结合，结果表明 MbtB_Cy 结合袋对吸电子官能团具有很强的亲和力，有助于稳定的极性相互作用。酶和配体。此外，与针对金黄色分枝杆菌的中等体外抗分枝杆菌功效（64 μg/mL）相比，TSA-5 对受感染的巨噬细胞中的金分枝杆菌具有增强的细胞内杀伤功效（8 μg/mL）。

  DOI：

  10.3390/molecules28248115

文献信息

• NMR spectra of intramolecularly hydrogen-bonded compounds—II
  作者：N.M.D. Brown、D.C. Nonhebel

  DOI：10.1016/0040-4020(68)88164-5

  日期：1968.1

  Schiff bases of aromatic amines and β-diketones including those containing Ph end-groups have been shown to exist as the keto-amine tautomer using NMR spectroscopy. The Schiff bases derived from aromatic amines and 2-hydroxyl-1-naphthaldehyde were concluded to be an equilibrium mixture of the ketoenamine and enolimine forms. The influence of electronic effects in the aromatic amines on the hydrogen-bond

  使用NMR光谱法已显示芳香胺和β-二酮的席夫碱（包括含Ph端基的席夫碱）作为酮胺互变异构体存在。衍生自芳族胺和2-羟基-1-萘醛的席夫碱被认为是酮烯胺和烯醇胺形式的平衡混合物。还研究了芳族胺中电子效应对氢键强度的影响。
• Surprising Insights in the Various Molecular Structures of Hypercoordinate Bis(oxinato)silicon Complexes
  作者：Jörg Wagler、Michael Schley、Daniela Gerlach、Uwe Böhme、Erica Brendler、Gerhard Roewer

  DOI：10.1515/znb-2005-1006

  日期：2005.10.1

  The syntheses of two cyclic diorganosilicon enamines =CH₂) [R = Ph (2a), Me (2b)] are described. These compounds react with 8-oxyquinoline leading to bis(oxinato)silicon complexes RPhSi(oxinate)2 [R = Ph (5a), Me (5b)]. Their X-ray structures reveal hexacoordination of the Si atom with the monodentate substituents in cis-positions and N atoms as well as O atoms in trans-positions.

  In crystalline dimethylbis(oxinato)silicon, Me₂Si(oxinate)₂ (7), the silicon atom is only bicapped tetrahedrally coordinated, while for dichlorobis(oxinato)silicon, Cl₂Si(oxinate)₂ (8), there is an octahedral coordination of the Si atom with chlorine atoms in trans-positions. This conclusion is based on the results of spectroscopic analysis (IR, ²⁹Si CP/MAS NMR) as well as quantum chemical calculations. The first example of a silicon-bis-oxinate with the N→Si dative bonds in a trans-arrangement has been detected in the hexacoordinate silicon tris-chelate (oxinate)₂Si(PhN-CH₂CH₂-NPh) (11). Its configuration was proven by X-ray structure analysis. Thus, for hexacoordinate bis(oxinato)silicon compounds three new architectures were found which complement the previously established building pattern of the N,N’-cis-O,O’-trans-bis(oxinato)silicon complexes.

  The mer-tris(oxinato)siliconium cation (9⁺) (its configuration being proven by ¹H and ¹³C NMR spectroscopy) features at least three coordination patterns with (O,O;N,N)-cis,cis-, -cis,trans- as well as -trans,cis-arrangements of two oxinate ligands.

  两种环状二有机硅烯胺的合成=CH₂) [R = Ph (2a), Me (2b)]已描述。这些化合物与8-羟基喹啉反应，形成双(羟酸盐)硅络合物RPhSi(oxinate)2 [R = Ph (5a), Me (5b)]。它们的X射线结构显示硅原子的六配位，单齿取代基位于顺式位置，N原子以及O原子位于反式位置。 在结晶的二甲基双(羟酸盐)硅Me₂Si(oxinate)₂ (7)中，硅原子仅双顶四面体配位，而对于二氯双(羟酸盐)硅Cl₂Si(oxinate)₂ (8)，硅原子具有八面体配位，氯原子位于反式位置。这一结论基于光谱分析结果（红外光谱，²⁹Si CP/MAS NMR）以及量子化学计算。在六配位硅三螯合物(oxinate)₂Si(PhN-CH₂CH₂-NPh) (11)中，首次发现了N→Si配位键以反式排列的硅-双-羟酸盐的例子。其构型经X射线结构分析证实。因此，对于六配位双(羟酸盐)硅化合物，发现了三种新的结构，这些结构补充了先前建立的N,N’-顺式-O,O’-反式双(羟酸盐)硅络合物的构建模式。 mer-三(羟酸盐)硅阳离子(9⁺)（其构型经¹H和¹³C NMR光谱证实）至少具有三种配位模式，包括（O,O;N,N）-顺,顺-，-顺,反-以及-反,顺-排列的两个羟酸盐配体。
• AN IMPROVED SOLVENT-FREE PREPARATION OF 2-IMIDOYLPHENOLS
  作者：Cristina Cimarelli、Gianni Palmieri、Emanuela Volpini

  DOI：10.1080/00304940109356602

  日期：2001.8

  several applications and as precursors for some classes of molecules. They serve as ligands' in the preparation of rhodium complex catalysts, possess interesting antifungal properties,' and are starting materials for the synthesis of 4H-chromen-4-ylidenamines.' Moreover, the stereoselective reduction of imidoyl phenols is a convenient synthetic pathway to aminophenols, another class of ligands extremely

  2-亚氨基酚 (3) 是杂官能取代的有机化合物，用于多种应用并作为某些类别分子的前体。它们在铑配合物催化剂的制备中用作配体，具有有趣的抗真菌特性，并且是合成 4H-chromen-4-ylidenamines 的起始材料。此外，亚氨基酚的立体选择性还原是合成氨基酚的便捷途径，氨基酚是另一类在催化反应中非常有效的配体，例如通过有机锌化合物与醛的对映选择性加成来合成光学活性仲醇。
• Diagnostic/therapeutic agents
  申请人：Klaveness Jo

  公开号：US20050002865A1

  公开（公告）日：2005-01-06

  Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

  可定位的诊断和/或治疗活性剂，例如超声对比剂，包括悬浮在水载体液中的报告物，该报告物包含含气体或生成气体的材料，该剂能够与目标形成至少两种结合对。
• Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
  申请人：Counts David F.

  公开号：US10463611B2

  公开（公告）日：2019-11-05

  The present disclosure provides a once-daily water-soluble pharmaceutically active formulation for oral administration. In certain embodiments, the composition comprises a water-soluble pharmaceutically active organic compound incorporated into a small particulate, each particulate having a core of the water-soluble pharmaceutically active organic compound or an acceptable salt thereof in reversible association with a pharmaceutically acceptable drug-binding polymer. The core of the composition being surrounded by an insoluble water permeable membrane that is capable of delaying the dissolution of the pharmaceutically active compound therewithin and providing for extended release of the pharmaceutically active compound. In some embodiments, the formulation of the invention are designed to extend release of the pharmaceutically active organic compound for about 3 hours to about 8 hours, thereby enabling preparation of an extended release formulation for any pharmaceutically active compound with a half-life of from about 16 hours to about 21 hours.

  本公开提供了一种用于口服的每日一次水溶性药用活性制剂。在某些实施方案中，该组合物包括掺入小颗粒中的水溶性药用活性有机化合物，每个颗粒都有一个水溶性药用活性有机化合物或其可接受盐的核心，该核心与药学上可接受的药物结合聚合物可逆结合。组合物的核心由不溶性透水膜包围，该膜能够延迟其中的药用活性化合物的溶解，并延长药用活性化合物的释放时间。在某些实施方案中，本发明的制剂可将药用活性有机化合物的释放时间延长约 3 小时至约 8 小时，从而能够制备半衰期为约 16 小时至约 21 小时的任何药用活性化合物的缓释制剂。